Duavee

Chemical Nameconjugated estrogens/bazedoxifene
Dosage FormTablet (oral; 0.45 mg conjugated estrogens and 20 mg bazedoxifene)
Drug ClassHormones
SystemFemale reproductive
CompanyPfizer Inc.
Approval Year2013

Indication

  • For the treatment of moderate to severe vasomotor symptoms associated with menopause.
  • For the prevention of postmenopausal osteoporosis.
Last updated on 4/27/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Duavee (conjugated estrogens/bazedoxifene) Prescribing Information2013Wyeth Pharmaceuticals Inc., Philadelphia PA
Document TitleYearSource
The 2017 hormone therapy position statement of the North American Menopause Society.2017The Journal of The North American Menopause Society
Treatment of symptoms of the Menopause: An endocrine society clinical practice guideline.2015Journal of Clinical Endocrinology and Metabolism